Member Info for Prion25

“The planned longer-term toxicology studies are critical next steps, not only for regulatory purposes but also to enhance SDC-1801's value proposition for potential out-licensing partners.”

How long have been studying this molecule toxicity and how much further investigation is required to prove an already definitive outcome ?

"It's also worth noting that in holding a proffered paper session at the EORTC-NCI-AACR symposium, it is probable that Avacta is already sitting on some in-vivo (i.e. early pre-clinical) data."

Was good to see in the highly illuminating tweet by MM that the in vivo data which I referred to in my previous post probably already exists ! And the warhead may be Gilead 's SN-38 Topoisomerase using our much cheaper non monoclonal PDC .Its all looking good

“Avacta will present in vivo data that demonstrates the ability to target and accumulate the active warhead in the tumor microenvironment, resulting in tumor growth inhibition with AVA6103.”

Could be mouse data with new Topoisomerase warhead

They have in Vivo data for Ava 6103 to be presented This is new ?

Ttps://www.atkinsrealis.com/en/media/trade-releases/2024/27-02-2024

I had forgotten the significance of Atkins Realis

BuenaVista

William Bachovchin patents are impressive

https://patents.justia.com/inventor/william-w-bachovchin

I suppose in 2018 with the partnership of Bach Biosciences / Tufts with Avacta affirmer and Precision tech was a master stroke probably down to AS ? Whoever , the science is novel and compelling and bodes well for cancer suffers and investors imo

Thanks DS just skip through for now a big read

A million compounds investigated ?Must be AI driven ? The positive Rhabdosarcoma data must bode well for us in cancer treatments and sulforaphane “neurological “ mode of action in brain imho

FAP pro drugs for breast and prostate cancer particularly exciting

Almostrich

Spot on !

D . Bank shameful incompetence and shenanigans exposed

Thanks JB

Yes there are connection issues

Yes I suspect there will be a fundraise going forward

Parry-Billings said he has "followed Synairgen's approach to SNG001 as a potential broad-spectrum antiviral for a wide range of severe lung infections for some time and look forward to working with the board and broader team on its clinical development in a crucial area of unmet need".

What’s going on ? I think is intentions are has he described above not to dissolve the company ?

Missed it , did Lammy mention hydrogen in his climate Speech today

Who are you going to trust the dark forces of spiv analyst working for the city and big pharma predators or the scientist /oncologists already proven the can improve the quality of life of cancer suffers with AVA6K chemo and potentially there will be improved efficacy PFS and OS with new warheads and combination therapies GLA

Https://www.bbc.co.uk/news/articles/c23ljy4z05mo

As discussed before the power consumption of data centres and Ceres tech as the solution to this critical infrastructure

PM was the "front man "to communicate to the scientific community at various conferences that the granular data obtained from the P3 botch up was enough to demonstrate that sng001 still had potential in a very vulnerable sub group. Nobody was swayed and I think PM the front man has now become the fall guy for the lack of progress since P3

130 clean energy ,Wind , Solar and Tidal contracts handed out by Ed Windbag "new jobs "mostly to Danish company no mention yet of Hydrogen The Sunak Boris GoV made a big commitment to Hydrogen when the wind does not blow or the sun does not shine

Feels like desperation ,damage limitation and praying for a life line before AGM . Very sad news

Complete response (CR): The tumor disappears

Partial response (PR): The tumor shrinks

Stable disease (SD): The tumor stays the same

Progressive disease (PD): The tumor gets bigger

The article reminded me about RECIST 1:1 criteria above and it could be the longer the trial goes on the more likely hood of (CR) / improved outcomes

Doxrubicin when not in combination the efficacy rates of doxorubicin treatment can vary depending on the type of cancer for example for patients with advanced soft tissue sarcoma, doxorubicin-based chemotherapy has shown response rates of approximately 25%. The median progression-free survival is around 4-7 months, and overall survival ranges from 12-17 months and you have to factor in serious the toxicity effects of Dox . So the trials results we are expecting the bar in my opinion has been set relatively low .AVA6000 prodrug will reduce toxicity and improve efficacy so there so much to be optimistic about and the potential of new warheads and combination therapies

Good find DSFLAT new research tools on brain mapping being developed - lets hope that Sulforaphane intervention will be proved beneficial more rapidly through clinical trials